LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 35 of 66
Next
>>
>
851 to 875 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Neratinib	180619_MC_11	886	0.1506	77	68	9	8	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_5	145	0.1406	635.9	71.1	15071	356.7	0.0231	0.11757	0.0753
Neratinib	180619_MC_11	1116	0.1233	76	71	14	13	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_6	147	0.1164	635.9	71.1	15071	356.7	0.0231	0.09332	0.1311
Neratinib	180619_MC_12	1719	0.0450	59	21	6	10	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_7	80	0.0445	635.9	71.1	15071	356.7	0.0231	0.02139	0.2433
Neratinib	180619_MC_12	1304	0.1772	146	111	7	3	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_8	257	0.1646	635.9	71.1	15071	356.7	0.0231	0.14156	0.1703
Neratinib	180619_MC_12	1520	0.1224	147	57	7	7	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_9	204	0.1183	635.9	71.1	15071	356.7	0.0231	0.09526	0.2102
Neratinib	180619_MC_10	744	0.3086	79	175	4	22	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_1	254	0.2545	635.9	71.1	15071	356.7	0.0231	0.23143	0.0350
Neratinib	180619_MC_10	612	0.4476	123	206	5	19	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_2	329	0.3496	635.9	71.1	15071	356.7	0.0231	0.32655	-0.0083
Neratinib	180619_MC_10	549	0.4209	102	172	9	9	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_3	274	0.3329	635.9	71.1	15071	356.7	0.0231	0.30985	-0.0317
Neratinib	180619_MC_11	858	0.2778	103	164	5	12	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_4	267	0.2373	635.9	71.1	15071	356.7	0.0231	0.21426	0.0678
Neratinib	180619_MC_11	766	0.2991	100	159	8	19	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_5	259	0.2527	635.9	71.1	15071	356.7	0.0231	0.22961	0.0416
Neratinib	180619_MC_11	783	0.2226	84	109	9	20	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_6	193	0.1977	635.9	71.1	15071	356.7	0.0231	0.17467	0.0466
Neratinib	180619_MC_12	920	0.1792	107	77	4	22	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_7	184	0.1667	635.9	71.1	15071	356.7	0.0231	0.14359	0.0842
Neratinib	180619_MC_12	900	0.1740	106	69	8	14	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_8	175	0.1628	635.9	71.1	15071	356.7	0.0231	0.13972	0.0790
Neratinib	180619_MC_12	926	0.1793	100	84	13	14	Neratinib	3.160329364	treatment	72	2	MCF10A-GM_9	184	0.1658	635.9	71.1	15071	356.7	0.0231	0.14269	0.0858
Taxol	180619_MC_10	14915	0.0225	72	265	7	15	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_1	337	0.0221	635.9	71.1	15071	356.7	0.0231	-0.00098	0.9954
Taxol	180619_MC_10	13886	0.0195	41	231	12	5	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_2	272	0.0192	635.9	71.1	15071	356.7	0.0231	-0.00386	0.9645
Taxol	180619_MC_10	14425	0.0199	26	261	13	7	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_3	287	0.0195	635.9	71.1	15071	356.7	0.0231	-0.00357	0.9809
Taxol	180619_MC_11	15058	0.0252	58	323	6	13	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_4	381	0.0247	635.9	71.1	15071	356.7	0.0231	0.00160	0.9996
Taxol	180619_MC_11	14710	0.0258	55	326	8	13	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_5	381	0.0252	635.9	71.1	15071	356.7	0.0231	0.00217	0.9894
Taxol	180619_MC_11	14696	0.0246	59	304	13	17	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_6	363	0.0241	635.9	71.1	15071	356.7	0.0231	0.00103	0.9890
Taxol	180619_MC_12	15484	0.0279	118	318	9	20	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_7	436	0.0274	635.9	71.1	15071	356.7	0.0231	0.00431	1.0119
Taxol	180619_MC_12	16311	0.0227	95	277	10	20	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_8	372	0.0223	635.9	71.1	15071	356.7	0.0231	-0.00078	1.0349
Taxol	180619_MC_12	15528	0.0273	126	302	13	20	Paclitaxel	0.000332667	treatment	72	2	MCF10A-GM_9	428	0.0268	635.9	71.1	15071	356.7	0.0231	0.00375	1.0131
Taxol	180619_MC_10	14574	0.0303	88	356	3	16	Paclitaxel	0.000998	treatment	72	2	MCF10A-GM_1	444	0.0296	635.9	71.1	15071	356.7	0.0231	0.00649	0.9854
Taxol	180619_MC_10	12128	0.0235	57	229	12	7	Paclitaxel	0.000998	treatment	72	2	MCF10A-GM_2	286	0.0230	635.9	71.1	15071	356.7	0.0231	-0.00004	0.9071

|<
<<
Previous
Page 35 of 66
Next
>>
>
851 to 875 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)